Haptoglobin (Hp) binds the globin portion of free haemoglobin (Hb) thus inhibiting oxidative damage: it also has anti-inflammatory and pro-angiogenic properties. There are two Hp alleles and three phenotypes, Hp 1-1, Hp 2-1, and Hp 2-2; the latter is present in ∼50% of people, and is associated with cardiovascular risk and declining renal function in diabetes patients. Preeclampsia (PE) occurs more frequently in diabetic than nondiabetic women (∼20% vs. ∼5%): reasons are not fully elucidated, but oxidative stress, inflammation, and altered angiogenesis are implicated.

We determined maternal plasma Hp levels (ELISA, R and D Systems) and Hp phenotype (ELISA, Savyon Diagnostics Ltd.) in a prospective study of 23 pregnant women with type 1 diabetes (T1D) who developed PE, 24 who remained normotensive, and 19 pregnant normotensive nondiabetic women. Samples were collected at 3 visits (V1-V3) (12.4 ± 1.8, 21.7 ± 1.4, and 31.3 ± 1.4 weeks gestation (mean ± SD)). All subjects were free of microalbuminuria and hypertension at enrolment, and all visits preceded clinical PE onset.

Results: Longitudinal analyses revealed significant temporal decreases of plasma Hp during pregnancy in T1D women who developed PE (p=0.001) and in nondiabetic normotensive women (p=0.017), but not in T1D who remained normotensive. Among all T1D women, plasma Hp was lower in those with Hp 2-2 vs. ’non-Hp 2-2’ phenotype at V2 (p=0.005) and V3 (p=0.002), independent of PE status. In Hp 2-2 T1D women only, plasma Hp was higher in those who did vs. did not develop PE at V1 (77.0 ± 31.4 vs. 50.7 ± 14.5 (mg/dl)) (p=0.033) and V2 (61.9 ± 19.0 vs. 42.0 ± 21.5) (p=0.046). Plasma Hp correlated positively with CRP at all visits (p<0.01), but not with previously-measured anti-angiogenic/angiogenic factors.

Conclusion: Maternal plasma Hp may serve as an early marker for PE in T1D pregnancy, particularly in women with the Hp 2-2 phenotype.

Disclosure

C.B. Kelly: None. J. Yu: None. A. Jenkins: Research Support; Self; Medtronic, Mylan, Sanofi-Aventis. A.J. Nankervis: None. K.F. Hanssen: None. S.K. Garg: Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Sanofi US. Advisory Panel; Self; Sanofi US. Research Support; Self; MannKind Corporation, Diasome Pharmaceuticals, Inc., Labstyle Innovations, Lexicon Pharmaceuticals, Inc., Medtronic. Advisory Panel; Self; Novo Nordisk A/S. C.E. Aston: None. T. Lyons: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.